Publication #7411

Reference
CEM/CMO/2021/016
Name
COVID therapeutic alert – interleukin-6 inhibitors (tocilizumab or sarilumab) for patients hospitalised due to COVID-19
Categories
Scottish Government Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS SCOTLAND DRUGS SAFETY RISKS PHARMACEUTICAL INDUSTRY DRUG THERAPY PHARMACEUTICAL SERVICES
Description
Attaches a letter about the combined policy replacing previous separately published policies for sarilumab and tocilizumab respectively on 17 February 2021. A single UK Interim Clinical Commissioning Policy has now been published, recommending that equal consideration is given to two potential interleukin-6 (IL-6) inhibitor treatment options - tocilizumab or sarilumab - for adult patients (aged 18 years and older) hospitalised due to COVID-19 in accordance with the agreed criteria for onward transmission.

Contact Name
Contact Address
Contact Phone

Created
2021-09-13 00:00:00


Click to go back to homepage